Acorda Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $22.39 million
- Book Value:
- Revenue TTM:
- $124.06 million
- Operating Margin TTM:
- Gross Profit TTM:
- $78.46 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Acorda Therapeutics Inc had its IPO on 2006-02-10 under the ticker symbol ACOR.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Acorda Therapeutics Inc has a staff strength of 118 employees.
Shares of Acorda Therapeutics Inc opened at $0.55 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $0.5 - $0.6, and closed at $0.5.
This is a -8.73% slip from the previous day's closing price.
A total volume of 292,153 shares were traded at the close of the day’s session.
In the last one week, shares of Acorda Therapeutics Inc have slipped by -22.77%.
Acorda Therapeutics Inc's Key Ratios
Acorda Therapeutics Inc has a market cap of $22.39 million, indicating a price to book ratio of 0.1677 and a price to sales ratio of 0.1079.
In the last 12-months Acorda Therapeutics Inc’s revenue was $124.06 million with a gross profit of $78.46 million and an EBITDA of $-11889000. The EBITDA ratio measures Acorda Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Acorda Therapeutics Inc’s operating margin was -36.13% while its return on assets stood at -6.52% with a return of equity of -87.93%.
In Q3, Acorda Therapeutics Inc’s quarterly earnings growth was a positive 587.3% while revenue growth was a positive 6.5%.
Acorda Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-6.24 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0.51. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Acorda Therapeutics Inc’s profitability.
Acorda Therapeutics Inc stock is trading at a EV to sales ratio of 1.4973 and a EV to EBITDA ratio of -14.6965. Its price to sales ratio in the trailing 12-months stood at 0.1079.
Acorda Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $393.34 million
- Total Liabilities
- $42.02 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Acorda Therapeutics Inc ended 2023 with $393.34 million in total assets and $0 in total liabilities. Its intangible assets were valued at $393.34 million while shareholder equity stood at $75.77 million.
Acorda Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $42.02 million in other current liabilities, 24000.00 in common stock, $-955415000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $20.70 million and cash and short-term investments were $20.70 million. The company’s total short-term debt was $1,454,000 while long-term debt stood at $187.69 million.
Acorda Therapeutics Inc’s total current assets stands at $71.69 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $14.69 million compared to accounts payable of $11.51 million and inventory worth $15.25 million.
In 2023, Acorda Therapeutics Inc's operating cash flow was $-150000.00 while its capital expenditure stood at $150000.
Comparatively, Acorda Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Acorda Therapeutics Inc stock is currently trading at $0.5 per share. It touched a 52-week high of $2.16 and a 52-week low of $2.16. Analysts tracking the stock have a 12-month average target price of $10.
Its 50-day moving average was $0.59 and 200-day moving average was $0.63 The short ratio stood at 1.09 indicating a short percent outstanding of 0%.
Around 68.5% of the company’s stock are held by insiders while 2074.3% are held by institutions.
Frequently Asked Questions About Acorda Therapeutics Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson’s disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.